About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Adrià Molero Valenzuela, Pre-doctoral researcher, Childhood Cancer and Blood Disorders Group. Vall d’Hebron Institut de Recerca (VHIR)
Abstract: Half of neuroblastoma (NB) patients present with metastatic disease at diagnosis, most commonly affecting bone and bone marrow (90%), lymph nodes (35%), liver (20%), or lungs (5%). Given the low mutational burden that characterizes most childhood cancers, increasing evidence suggests that epigenetic plasticity rather than genetic diversity drives NB progression and dissemination. We hypothesize that epigenetic reprogramming enables tumor cells to adapt to distinct metastatic microenvironments, conferring the phenotypic flexibility required for colonization, survival and outgrowth in distant organs. Therefore, elucidating chromatin structure alterations and the epigenetic traits underlying metastatic adaptation will deepen our understanding of disease evolution and may uncover novel therapeutic vulnerabilities.
Host: Dr. Miguel Segura Ginard, Main researcher Childhood Cancer and Blood Disorders. Vall d’Hebron Institut de Recerca (VHIR)
